ARS Pharmaceuticals, Inc. specializes in creating ARS-1, an innovative intranasal epinephrine spray utilizing advanced absorption technology. This product serves as a crucial ...
ARS Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company headquartered in San Diego, California, and traded on the Nasdaq Global Market under the symbol SPRY. Founded in 2015, the company focuses on improving emergency treatment for severe allergic reactions, particularly anaphylaxis caused by foods, medicines, or insect stings. Its core strategy ...ARS Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company headquartered in San Diego, California, and traded on the Nasdaq Global Market under the symbol SPRY. Founded in 2015, the company focuses on improving emergency treatment for severe allergic reactions, particularly anaphylaxis caused by foods, medicines, or insect stings. Its core strategy is to address limitations associated with injectable epinephrine, including needle-related anxiety, portability, administration complexity, and the possibility that patients or caregivers may hesitate to use an auto-injector during an emergency.
The company’s principal product is neffy, a low-dose intranasal epinephrine spray. Neffy is designed to deliver epinephrine through the nasal cavity using ARS Pharmaceuticals’ absorption technology. The product is intended for patients and caregivers who need a rapid, convenient, and needle-free emergency treatment option. The underlying ARS-1 platform is central to the company’s product development strategy and may support additional applications where reliable systemic absorption through the nose could be clinically useful. The company’s commercial opportunity is tied to the large population of people with severe allergies, the need for rapid treatment, and increased awareness of anaphylaxis preparedness in households, schools, workplaces, and public settings.
ARS Pharma operates as a specialized biotechnology and pharmaceutical business rather than a diversified drug manufacturer. Its activities include research and development, regulatory work, manufacturing coordination, product commercialization, market access, medical education, and support for patients and caregivers. Specific bill-of-materials details, manufacturing costs, supplier arrangements, and unit economics are not provided in the supplied information. As with many emerging biopharmaceutical companies, expenses can include clinical and regulatory programs, product manufacturing and inventory, sales and marketing, employee compensation, intellectual property, and post-approval commercial activities.
The company is led by Donn Casale, who serves as President, Chief Executive Officer, and a director. Richard Lowenthal co-founded ARS Pharmaceuticals in 2015 and previously served as President and CEO; he is associated with the development and launch of neffy and the company’s earlier growth. The reported workforce is 158 employees, placing ARS Pharma in the 101-200 employee category. The company emphasizes inclusivity, integrity, creativity, and patient-focused innovation in its corporate culture.
According to the supplied trailing-twelve-month financial data, ARS Pharma had approximately $84 million in reported revenue-related scale based on the cited company profile, a gross margin of approximately 77.1%, and continued operating and net losses. The data also shows strong liquidity, including a current ratio of about 4.94, but negative operating cash flow and free cash flow, reflecting ongoing investment in commercialization and business development. The company reported no dividend. Its future performance depends on neffy adoption, reimbursement and market access, physician and caregiver acceptance, manufacturing execution, regulatory developments, competitive products, and its ability to fund operations while expanding the commercial opportunity for needle-free epinephrine.
YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.
QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).
$84.3M
-5.5%
+48.4%
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.
$-171.3M
-2241.8%
-2.8%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.
+75.8%
-1.5%
-14.5%
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).
-212.9%
-6057.0%
+31.1%
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.
-203.3%
-2365.5%
+30.7%
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.
$-171.2M
-1418.5%
-35.6%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.
-203.1%
-1494.7%
+8.7%
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.
84.3%
+515621.9%
+771.1%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.
7.28x
-49.0%
-29.7%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.
Operator: Good afternoon, and welcome to ARS Pharma second-quarter 2026 earnings conference call. At this time, all participants are in a listen-only mode. After the company's prepared remarks, we will open the line for questions. Please be advised that today's conference is being recorded. I will now turn the call over to Monique Allaire, IR representative for the company. Please go ahead.
Monique Allaire: Good afternoon, and thank you for joining us. With me on the call today is Donn Casale, President and CEO of ARS Pharma. Kathy Scott, our Chief Financial Officer, will join us for the Q&A session. Earlier today, we issued a press release outlining ARS Pharma corporate priorities and commercial highlights and detailing its financial results for the second quarter of 2026. That press release can be found in the Investors and Media section of the company's website at ars-pharma.com. Before we begin, please note that today's remarks may contain forward-looking statements and actual results may differ materially. Please refer to our press release and SEC filings for further risk disclosures. With that, I'll turn the call over to Donn.
Donn Casale: Thank you, Monique, and good afternoon, everyone. It's an absolute honor to host my first earnings call as CEO. This is a pivotal time for ARS Pharmaceuticals, and I look forward to sharing my strategic vision today, along with the corporate priorities that will drive our next chapter of growth. Over the past month, I've conducted a deep review with our commercial, clinical, and corporate teams and met with many of our investors and shareholders. Those conversations confirm both the significant market opportunity ahead and the need for a disciplined operational approach going forward. Today, I want to walk you through how I see the business, what's working, what's changing, and what to expect from ARS. What I'm outlining is more than a shift in our commercial strategy. It is a fundamental change in how we manage our business and allocate capital. Against that backdrop, I'm laying out three strategic priorities that will guide our next phase. First, targeted provider commercial execution. We are prioritizing our resources and focus where they make the greatest immediate impact on neffy market share, the healthcare provider. Second, financial discipline. We are implementing a rigorous strategic cost optimization framework, significantly reducing SG&A expense with a focus on building a profitable neffy franchise with a predictable path to cash-flow breakeven. Third, pipeline expansion, starting with chronic spontaneous urticaria, or CSU. We are extending our intranasal epinephrine platform into a second large market, where we see significant opportunity to bring the first FDA-approved treatment for CSU acute flares. CSU addresses a critical unmet need and offers a compelling market expansion opportunity. Let me expand on the first strategic priority in more detail. Targeted provider commercial execution. …
